Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Non-Current Deferred Tax Liability (2023 - 2026)

Barinthus Biotherapeutics filings provide 4 years of Non-Current Deferred Tax Liability readings, the most recent being $237000.0 for Q1 2026.

  • On a quarterly basis, Non-Current Deferred Tax Liability fell 43.03% to $237000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $237000.0, a 43.03% decrease, with the full-year FY2025 number at $254000.0, down 97.52% from a year prior.
  • Non-Current Deferred Tax Liability hit $237000.0 in Q1 2026 for Barinthus Biotherapeutics, down from $254000.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $11.8 million in Q4 2023 to a low of $237000.0 in Q1 2026.
  • Median Non-Current Deferred Tax Liability over the past 4 years was $403500.0 (2025), compared with a mean of $3.0 million.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: fell 12.76% in 2024 and later crashed 97.52% in 2025.
  • Barinthus Biotherapeutics' Non-Current Deferred Tax Liability stood at $11.8 million in 2023, then decreased by 12.76% to $10.3 million in 2024, then plummeted by 97.52% to $254000.0 in 2025, then fell by 6.69% to $237000.0 in 2026.
  • The last three reported values for Non-Current Deferred Tax Liability were $237000.0 (Q1 2026), $254000.0 (Q4 2025), and $320000.0 (Q3 2025) per Business Quant data.